Real-World Determinants of Olanzapine Prescribing for Antiemetic Prophylaxis in Adults Receiving Highly-Emetogenic Chemotherapy
Authors:
Open Access
- 15 December 2025
- journal article
- Published by SAGE Publications in Hospital Pharmacy
- Vol. 61 (3) , 279-289
Abstract
Background: Since 2017, guidelines recommend a four-drug prophylactic antiemetic regimen—5HT3 receptor antagonist (5HT3RA), NK1 receptor antagonist (NK1RA), dexamethasone, and olanzapine—for patients receiving highly emetogenic chemotherapy (HEC). This study examines prophylactic olanzapine prescribing in patients initiating HEC and associated sociodemographic, clinical, and contextual factors. Methods: A retrospective cohort study was conducted using electronic health record data from an academic cancer center and affiliated community practices across the state of North Carolina, joined with geocoded community factors. Adults ≥21 years initiating cisplatin, carmustine, dacarbazine, mechlorethamine, streptozocin, or cyclophosphamide plus anthracycline (AC) in 2022 were included. Antiemetic orders placed before HEC administration were classified as three-drug (5HT3RA, NK1RA, dexamethasone) or four-drug (plus olanzapine). Late olanzapine use (within 30 days post-HEC) was also assessed. Multivariable logistic regression evaluated factors associated with regimen type. Results: Among 878 patients, all received orders for the three-drug regimen, but only 300 (34.2%) had olanzapine ordered within 30 days before first HEC. After adjusting for covariates, olanzapine prescribing was less likely in patients with breast (OR = 0.13, 95%CI = 0.07-0.23), gastrointestinal (OR = 0.20, 95%CI = 0.04-0.94), gynecological (OR = 0.14, 95%CI = 0.03-0.69), and head and neck (OR = 0.17, 95%CI = 0.05-0.66) compared to hematological cancers, in those receiving cisplatin (OR = 0.20, 95%CI = 0.06-0.70) and carmustine (OR = 0.02, 95%CI = 0.00-0.48) compared to AC, and in community (OR = 0.40, 95%CI = 0.27-0.61) versus academic settings. Prescribing was also lower among patients residing in low- (OR = 0.49, 95%CI = 0.25-0.93) or lower-middle income (OR = 0.50, 95%CI = 0.32-0.78) areas, but higher among those living >6 miles from treatment facilities (OR = 1.95, 95%CI = 1.08-3.58). Among patients without prophylactic olanzapine, 12.5% were prescribed it within 1 to 30 days post-HEC. Conclusions: Despite guideline recommendations, prophylactic olanzapine use in HEC remains suboptimal, influenced by clinical and non-clinical contextual factors. Targeted efforts at information dissemination and updated prescribing systems are needed to promote equitable, evidence-based supportive care.Keywords
Funding Information
- National Center for Advancing Translational Sciences (UM1TR004406)
This publication has 26 references indexed in Scilit:
- Impact of chemotherapy-induced nausea and vomiting on health-related quality of life and resource utilization: A systematic reviewCritical Reviews in Oncology/Hematology, 2016
- Adherence to national guidelines for antiemesis prophylaxis in patients undergoing chemotherapy for lung cancerCancer, 2012
- The impact of chemotherapy-related nausea on patients' nutritional status, psychological distress and quality of lifeSupportive Care in Cancer, 2012
- Introduction: Understanding and Influencing Multilevel Factors Across the Cancer Care ContinuumJournal of the National Cancer Institute Monographs, 2012
- Impact on daily functioning and indirect/direct costs associated with chemotherapy-induced nausea and vomiting (CINV) in a US populationSupportive Care in Cancer, 2010
- Resource utilization and costs associated with chemotherapy-induced nausea and vomiting (CINV) following highly or moderately emetogenic chemotherapy administered in the US outpatient hospital settingSupportive Care in Cancer, 2010
- The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studiesThe Lancet, 2007
- Coding Algorithms for Defining Comorbidities in ICD-9-CM and ICD-10 Administrative DataMedical Care, 2005
- An Ecological Perspective on Health Promotion ProgramsHealth Education Quarterly, 1988
- On the receiving end—patient perception of the side-effects of cancer chemotherapyEuropean Journal of Cancer and Clinical Oncology, 1983